Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.33 AUD
Change Today -0.005 / -1.49%
Volume 74.5K
GBI On Other Exchanges
Symbol
Exchange
Berlin
As of 1:59 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

genera biosystems ltd (GBI) Snapshot

Open
A$0.31
Previous Close
A$0.34
Day High
A$0.33
Day Low
A$0.31
52 Week High
05/14/15 - A$0.36
52 Week Low
12/30/14 - A$0.17
Market Cap
32.8M
Average Volume 10 Days
42.5K
EPS TTM
A$-0.03
Shares Outstanding
99.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENERA BIOSYSTEMS LTD (GBI)

Related News

No related news articles were found.

genera biosystems ltd (GBI) Related Businessweek News

No Related Businessweek News Found

genera biosystems ltd (GBI) Details

Genera Biosystems Limited develops and commercializes multiplexed molecular diagnostic tests in Australia. The company develops molecular diagnostic tests based upon its proprietary AmpaSand bead-based technology that facilitates the multiplexing of tests by identifying individual clusters of beads within a larger pool. Its products include RTIplex, a multiplexed and automated PCR based test for upper respiratory tract analytes; and PapType, a molecular diagnostic test for the simultaneous detection and genotyping of high risk and low risk types of human papillomaviruses that cause cervical cancer or genital warts. The company also develops next-generation, ultra-sensitive, and real-time detection systems. Its products are used by commercial pathology providers. The company is based in Scoresby, Australia.

genera biosystems ltd (GBI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
Chief Scientific Officer, Executive Director ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

genera biosystems ltd (GBI) Key Developments

Genera Biosystems Enters into Agreement with Genecell Diagnostics Private Limited

Genera Biosystems has entered into an agreement with Genecell Diagnostics Private Limited to supply its AmpaSand based molecular diagnostics assays to two selected pathology groups in the Indian market. Under the agreement CSDA Genecell has been granted the right to distribute Generarsquo’s AmpaSand MDx assays to its CureHealth Diagnostics pathology lab subsidiary and SRL Diagnostics. Genera is working with Genecell to support it to undertake its internal assay validation in late August with commercial shipments of kits anticipated to take place late in third quarter of calendar year 2015 and first customer receipts expected early in fourth quarter of calendar year 2015.

Genera Biosystems Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Genera Biosystems Limited reported consolidated earnings results for the half year ended December 31, 2014. For the year, the company reported revenue of AUD 146,846 compared to AUD 82,849 a year ago. Loss before income tax expense was AUD 1,585,476 compared to AUD 1,268,272 a year ago. Loss after income tax expense for the half-year attributable to the owners of the company was AUD 1,585,476 or 1.76 cents per basic and diluted share compared to AUD 1,268,272 or 1.50 cents per basic and diluted share a year ago. Net cash used in operating activities was AUD 645,068 compared to AUD 721,207 a year ago. Payments for purchase of intangibles were AUD 159,289 compared to AUD 83,553 a year ago.

Genera Biosystems Limited, Annual General Meeting, Nov 28, 2014

Genera Biosystems Limited, Annual General Meeting, Nov 28, 2014., at 11:00 AUS Eastern Standard Time. Location: Offices of Grant Thornton,. Agenda: To receive and consider annual financial report for the financial year ended June 30, 2014 and the auditor's thereon; to consider the adoption of remuneration report; to consider the re-election of Mr. Lou Panaccio to the board; to consider the re-election of Mr. Karl Poetter to the board; to consider the ratification of the prior issue of securities; and to consider the approval of an additional 10% securities placement facility.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBI:AU A$0.33 AUD -0.005

GBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GBI.
View Industry Companies
 

Industry Analysis

GBI

Industry Average

Valuation GBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 98.6x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 94.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENERA BIOSYSTEMS LTD, please visit www.generabiosystems.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.